Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Capital Expenditures (2019 - 2025)

IDEAYA Biosciences' Capital Expenditures history spans 7 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 57.8% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $2.4 million, down 38.61%, while the annual FY2025 figure was $2.4 million, 38.61% down from the prior year.
  • Capital Expenditures for Q4 2025 was $1.7 million at IDEAYA Biosciences, up from -$1.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.4 million in Q3 2022 and bottomed at -$3.1 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $641500.0 (2022), against an average of $453450.0.
  • The largest YoY upside for Capital Expenditures was 2939.39% in 2021 against a maximum downside of 1045.15% in 2021.
  • A 5-year view of Capital Expenditures shows it stood at -$1.9 million in 2021, then crashed by 57.11% to -$3.1 million in 2022, then skyrocketed by 177.41% to $2.4 million in 2023, then plummeted by 53.46% to $1.1 million in 2024, then soared by 57.8% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Capital Expenditures are $1.7 million (Q4 2025), -$1.4 million (Q3 2025), and $663000.0 (Q2 2025).